Clinical Trials
51 trialsCOLIBRI-GI
UNICANCER
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
RAMIRIS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
AIO-KRK-0418
Charite University, Berlin, Germany
ParpVax2
Abramson Cancer Center at Penn Medicine
BEVANEC
Hospices Civils de Lyon
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
University of Alabama at Birmingham
TEDOPAM
GERCOR - Multidisciplinary Oncology Cooperative Group
SAMCO
Federation Francophone de Cancerologie Digestive
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Sun Yat-sen University
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
TheraOp
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
University of Campania Luigi Vanvitelli
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
CLavSyn
Centre Hospitalier Universitaire de Besancon
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Federation Francophone de Cancerologie Digestive
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fudan University
PelvEx II
Catharina Ziekenhuis Eindhoven
mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
PANTHEON
AIO-Studien-gGmbH
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
PANC-001
Roger Williams Medical Center
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Ruijin Hospital
CCRe-IV
Hospital Universitari de Bellvitge
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
Rabin Medical Center
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
Zhejiang University
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Erbitux MEtastatic Colorectal Cancer Strategy Study
Catholic University of the Sacred Heart
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
ULTRA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Peking University
Cetuximab Monotherapy Maintenance Treatment in mCRC
Ruijin Hospital
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
The First People's Hospital of Changzhou
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest
Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
Regione Lombardia
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
UNC Lineberger Comprehensive Cancer Center
wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients
Fudan University
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
Central European Cooperative Oncology Group
SLAP
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
Samsung Medical Center
Metastatic Gastric Cancer FFCD 03-07
University Hospital, Toulouse